1. Breast cancer in elderly women. Optimizing the treatment

   • Roberto Gennari
   • Riccardo A. Audisio

   Review 13 September 2007 Pages: 199 - 209

2. Akt plays an important role in breast cancer cell chemotaxis to CXCL12

   • Ming Zhao
   • Barbara M. Mueller
   • Ingrid U. Schraufstatter

   Preclinical Study 09 August 2007 Pages: 211 - 222

   

3. Effects of IL-12 gene therapy on spontaneous transgenic and transplanted breast tumors

   • Francesca Faggioli
   • Sabina Soldati
   • Maria Grazia Sacco

   Preclinical Study 09 August 2007 Pages: 223 - 226

   

4. Colocalisation of predicted exonic splicing enhancers in BRCA2 with reported sequence variants

   • Christopher A. Pettigrew
   • Nicola Wayte
   • Melissa A. Brown

   Preclinical Study 26 September 2007 Pages: 227 - 234

   

5. Consensus genes of the literature to predict breast cancer recurrence

   • Martin Lauss
   • Albert Kriegner
   • Christa Noehammer

   Preclinical Study 26 September 2007 Pages: 235 - 244

   

6. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis

   • Kay Savage
   • Samuel Leung
   • Jorge S. Reis-Filho

   Preclinical Study 03 October 2007 Pages: 245 - 256

   

7. Extracellular matrix, Rac1 signaling, and estrogen-induced proliferation in MCF-7 breast cancer cells

   • J-W. Xie
   • S. Z. Haslam

   Preclinical Study 13 September 2007 Pages: 257 - 268

   

8. Antibodies to 46-kDa retinal antigen in a patient with breast carcinoma and cancer-associated retinopathy

   • Maria Ejma
   • Marta Misiuk-Hojło
   • Wiesława Bartnik

   Preclinical Study 13 September 2007 Pages: 269 - 271

   

9. Differential gene expression profile in breast cancer-derived stromal fibroblasts

   • Christian F. Singer
   • Daphne Gschwantler-Kaulich
   • Ernst Kubista

   Preclinical Study 26 September 2007 Pages: 273 - 281

   

10. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice

    • Wen-Bo Wang
    • Yu-Lin Zhou
    • Ying-Lin Cao

    Preclinical Study 26 September 2007 Pages: 283 - 295

    

11. Central carbon metabolism in the progression of mammary carcinoma

    • Adam D. Richardson
    • Chen Yang
    • Jeffrey W. Smith

    Preclinical Study Open access 19 September 2007 Pages: 297 - 307

    

12. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

    • August Garin
    • Alexey Manikhas
    • Sergey Tjulandin

    Clinical Trial 13 September 2007 Pages: 309 - 315

    

13. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study

    • Rastko Golouh
    • Tanja Cufer
    • John W. M. Martens

    Clinical Trial 13 September 2007 Pages: 317 - 326

    

14. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

    • Stephen R. D. Johnston
    • Vladimir F. Semiglazov
    • Angela J. Howes

    Clinical Trial 13 September 2007 Pages: 327 - 335

    

15. Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial

    • Ian S. Dayes
    • Mark N. Levine
    • T. J. Whelan

    Clinical Trial 13 September 2007 Pages: 337 - 342

    

16. I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer

    • Krzysztof Rożnowski
    • Danuta Januszkiewicz-Lewandowska
    • Jerzy Nowak

    Clinical Trial 26 September 2007 Pages: 343 - 348

17. Does high surgeon and hospital surgical volume raise the five-year survival rate for breast cancer? A population-based study

    • Chin-Shyan Chen
    • Tsai-Ching Liu
    • Yung-Chang Lien

    Epidemiology 12 September 2007 Pages: 349 - 356

    

18. Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged ≤55 years

    • Jiachun Lu
    • Qingyi Wei
    • Li-E Wang

    Epidemiology 13 September 2007 Pages: 357 - 366

    

19. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans

    • Dezheng Huo
    • Hee-Jin Kim
    • Olufunmilayo I. Olopade

    Epidemiology 02 October 2007 Pages: 367 - 376

    

20. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history

    • Theodore Anagnostopoulos
    • Maroulio Pertesi
    • Drakoulis Yannoukakos

    Epidemiology 28 September 2007 Pages: 377 - 385

    

21. CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk

    • Sohee Han
    • Kyoung-Mu Lee
    • Daehee Kang

    Epidemiology 17 October 2007 Pages: 387 - 393

22. Standardization of pathologic complete response rates in breast cancer treatment

    • Michael Knauer
    • Alexander DeVries
    • Anton Haid

    Letter to the Editor 13 September 2007 Pages: 395 - 396